natgillin/translations-raw huggingface dataset:
Aranesp 500 micrograms solution for injection pre-filled syringe EU/1/01/185/031 1 Pack Blister
Aranesp 500 mikrograma otopina za injekciju u napunjenoj štrcaljki EU/1/01/185/031 pakiranje od 1 s blisterima
Aranesp 500 pen
Aranesp 500 brizgalica
Aranesp 500 syringe
Aranesp 500 štrcaljka
Aranesp 500 µg Darbepoetin alfa IV/SC
Aranesp 500 µg darbepoetin alfa i.v./s.c.
Aranesp 500 µg injection Darbepoetin alfa
Aranesp 500 µg injekcija darbepoetin alfa
Aranesp 60 micrograms solution for injection in pre-filled pen
Aranesp 60 mikrograma otopina za injekciju u napunjenoj brizgalici
Aranesp 60 micrograms solution for injection in pre-filled pen Darbepoetin alfa
Aranesp 60 mikrograma otopina za injekciju u napunjenoj brizgalici darbepoetin alfa
Aranesp 60 micrograms solution for injection in pre-filled pen Each pre-filled pen contains 1.14 mg of sodium in 0.3 ml.
Aranesp 60 mikrograma otopina za injekciju u napunjenoj brizgalici Jedna napunjena brizgalica sadrži 1,14 mg natrija u 0,3 ml.
Aranesp 60 micrograms solution for injection in pre-filled syringe
Aranesp 130 mikrograma otopina za injekciju u napunjenoj štrcaljki
Aranesp 60 micrograms solution for injection in pre-filled syringe Darbepoetin alfa
Aranesp 60 mikrograma otopina za injekciju u napunjenoj štrcaljki darbepoetin alfa
Aranesp 60 micrograms solution for injection in pre-filled syringe Each pre-filled syringe contains 1.14 mg of sodium in 0.3 ml.
Aranesp 60 mikrograma otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 1,14 mg natrija u 0,3 ml.
Aranesp 60 micrograms solution for injection in vial
Aranesp 60 mikrograma otopina za injekciju u bočici
Aranesp 60 micrograms solution for injection in vial Darbepoetin alfa
Aranesp 60 mikrograma otopina za injekciju u bočici darbepoetin alfa
Aranesp 60 micrograms solution for injection pre-filled pen EU/1/01/185/051 – 1 pack
Aranesp 60 mikrograma otopina za injekciju u napunjenoj brizgalici EU/1/01/185/051 – pakiranje od 1
Aranesp 60 micrograms solution for injection pre-filled syringe EU/1/01/185/013 1 Pack Blister
Aranesp 60 mikrograma otopina za injekciju u napunjenoj štrcaljki EU/1/01/185/013 pakiranje od 1 s blisterima
Aranesp 60 micrograms solution for injection vial EU/1/01/185/104 1 Pack
Aranesp 60 mikrograma otopina za injekciju u bočici
Aranesp 60 pen
Aranesp 60 brizgalica
Aranesp 60 syringe
Aranesp 60 štrcaljka
Aranesp 60 µg Darbepoetin alfa IV/SC
Aranesp 60 µg darbepoetin alfa i.v./s.c.
Aranesp 60 µg injection Darbepoetin alfa
Aranesp 60 µg injekcija darbepoetin alfa
Aranesp 80 micrograms solution for injection in pre-filled pen
Aranesp 80 mikrograma otopina za injekciju u napunjenoj brizgalici
Aranesp 80 micrograms solution for injection in pre-filled pen Darbepoetin alfa
Aranesp 80 mikrograma otopina za injekciju u napunjenoj brizgalici darbepoetin alfa
Aranesp 80 micrograms solution for injection in pre-filled pen Each pre-filled pen contains 1.52 mg of sodium in 0.4 ml.
Aranesp 80 mikrograma otopina za injekciju u napunjenoj brizgalici Jedna napunjena brizgalica sadrži 1,52 mg natrija u 0,4 ml.
Aranesp 80 micrograms solution for injection in pre-filled syringe Darbepoetin alfa
Aranesp 80 mikrograma otopina za injekciju u napunjenoj štrcaljki darbepoetin alfa
Aranesp 80 micrograms solution for injection in pre-filled syringe Each pre-filled syringe contains 1.52 mg of sodium in 0.4 ml.
Aranesp 80 mikrograma otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 1,52 mg natrija u 0,4 ml.
Aranesp 80 micrograms solution for injection pre-filled pen EU/1/01/185/052 – 1 pack
Aranesp 80 mikrograma otopina za injekciju u napunjenoj brizgalici EU/1/01/185/052 – pakiranje od 1
Aranesp 80 micrograms solution for injection pre-filled syringe EU/1/01/185/015 1 Pack Blister
Aranesp 80 mikrograma otopina za injekciju u napunjenoj štrcaljki EU/1/01/185/015 pakiranje od 1 s blisterima
Aranesp 80 pen
Aranesp 80 brizgalica
Aranesp 80 syringe
Aranesp 80 štrcaljka
Aranesp 80 µg Darbepoetin alfa IV/SC
Aranesp 80 µg darbepoetin alfa i.v./s.c.
Aranesp 80 µg injection Darbepoetin alfa
Aranesp 80 µg injekcija darbepoetin alfa
Aranesp can be injected by the patient or their carer if they have been trained appropriately.
Aranesp mogu injicirati bolesnici ili njihovi skrbnici ako su za to prikladno izvježbani.
Aranesp exists in various strengths, from 25 to 500 micrograms per millilitre.
Aranesp postoji u različitim jačinama, od 25 do 500 mikrograma po mililitru.
Aranesp has also been compared with placebo (a dummy treatment) in two studies involving 669 patients receiving chemotherapy for cancer such as lung cancer, myeloma or lymphoma.
Aranesp je uspoređivan i s placebom (liječenje bez djelatne tvari) u dva ispitivanja koja su uključivala 669 bolesnika koji su primali kemoterapiju za rak, kao što je rak pluća, mijelom ili limfom.
Aranesp has also been studied in 124 children with chronic renal failure to check that it is absorbed in the same way as in adults.
Aranesp je ispitan i na 124-ero djece s kroničnim zatajenjem bubrega kako bi se provjerila njegova apsorpcija na isti način kao kod odraslih osoba.
Aranesp has been studied in patients with chronic renal failure in four studies involving over 1,200 patients, in which it was compared with recombinant human erythropoietin.
Aranesp je ispitan na bolesnicima s kroničnim zatajenjem bubrega u četiri ispitivanja koja su uključivala više od 1200 bolesnika, u kojima se uspoređivao s rekombinantnim ljudskim eritropoetinom.
Aranesp has no or negligible influence on the ability to drive and use machines.
Aranesp ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Aranesp is a clear, colourless or slightly pearly solution for injection in a pre-filled pen.
Aranesp je bistra, bezbojna ili blago biserna otopina za injekciju u napunjenoj brizgalici.
Aranesp is a solution for injection in a vial, a pre-filled syringe or a pre-filled pen.
Aranesp je otopina za injekciju u bočici, napunjenoj šprici ili napunjenoj brizgalici.
Aranesp is supplied ready for use in a pre-filled syringe.
Aranesp je dostupan spreman za primjenu u napunjenoj štrcaljki.
Aranesp is used to treat anaemia (low red blood cell counts) that is causing symptoms.
Aranesp se koristi za liječenje simptomatske anemije (nizak broj crvenih krvnih stanica).
Aranesp must not be used in people who are hypersensitive (allergic) to darbepoetin alfa or any of the other ingredients.
Aranesp se ne smije upotrebljavati kod osoba koje su preosjetljive (alergične) na darbepoetin alfa ili neku od drugih sastavnica.
Aranesp should be administered either subcutaneously or intravenously in order to increase haemoglobin to not greater than 12 g/dl (7.5 mmol/l).
Aranesp treba primijeniti supkutano ili intravenski kako bi se hemoglobin povisio na vrijednost koja nije veća od 12 g/dl (7,5 mmol/l).
Aranesp SureClick Pre-filled pen - Read package leaflet before use
Aranesp SureClick napunjena brizgalica – Prije uporabe pročitajte Uputu o lijeku
Aranesp therapy should be discontinued approximately four weeks after the end of chemotherapy.
Terapiju Aranespom treba prekinuti otprilike 4 tjedna nakon završetka kemoterapije.
Aranesp treatment should be initiated by a doctor who has experience in treating the types of anaemia mentioned above.
Liječenje lijekom Aranesp mora započeti liječnik koji ima iskustva s liječenjem prethodno spomenutih vrsta anemije.
Aranesp treatment should be initiated by physicians experienced in the above mentioned indications.
Liječenje Aranespom mora započeti liječnik koji ima iskustva u gore navedenim indikacijama.
Aranesp was as effective as human recombinant erythropoietin at increasing the haemoglobin levels in patients with chronic renal failure, and at keeping these levels maintained after they had been improved, whether given as an injection into a vein or under the skin.
Aranesp je bio jednako učinkovit kao rekombinantni ljudski eritropoetin za povećanje razina hemoglobina kod bolesnika s kroničnim zatajenjem bubrega i za održavanje tih razina nakon poboljšanja, neovisno o intravenskoj ili supkutanoj primjeni.
Arava 10 mg film-coated tablets
Arava 10 mg filmom obložene tablete
Arava 10 mg film-coated tablets are white to almost white and round.
Arava 10 mg filmom obložene tablete su bijele do gotovo bijele i okrugle.
Arava 100 mg film-coated tablets
Arava 100 mg filmom obložene tablete
Arava 100 mg film-coated tablets are white to almost white and round.
Arava 100 mg filmom obložene tablete su bijele do gotovo bijele i okrugle.
Arava 20 mg film-coated tablets
Arava 20 mg filmom obložene tablete
Arava 20 mg film-coated tablets are yellowish to ochre and triangular.
Arava 20 mg filmom obložene tablete su žućkaste do oker boje i trokutastog oblika.
Arava is contraindicated in pregnancy (see section 4.3).
Arava je kontraindicirana u trudnoći (vidjeti dio 4.3).
Arava is not recommended for use in children and adolescents below 18 years of age.
Arava se ne preporučuje za primjenu u djece i adolescenata mlađih od 18 godina.
Arava is not recommended for use in patients below 18 years since efficacy and safety in juvenile rheumatoid arthritis (JRA) have not been established (see sections 5.1 and 5.2).
Arava se ne preporučuje bolesnicima mlađima od 18 godina, jer djelotvornost i sigurnost primjene kod juvenilnog reumatoidnog artritisa (JRA) nisu ustanovljene (vidjeti dio 5.1 i 5.2).
Arava treatment usually starts with a ‘loading dose’ of 100 mg once a day for three days, followed by a maintenance dose.
Terapija lijekom Arava najčešće se započinje „dozom punjenja“ od 100 mg jednom na dan tijekom tri dana, nakon čega slijedi doza održavanja.
arcoidosis (a disease characterised by persistent fever, weight loss, joint pain and swelling, skin lesions and swollen glands), vasculitis.
arkoidoza (bolest koju prati stalna vrućica, gubitak tjelesne težine, bol i oticanje zglobova, oštećenja kože i povećanje limfnih čvorova), vaskulitis.
arcoidosis (rare).
arkoidoza (rijetko).
ARDS is uncommon in patients with cancer;
ARDS je manje čest kod bolesnika s karcinomom;
ARDS is uncommon in patients with cancer;
ARDS je manje čest u bolesnika s malignom bolešću.
ARDS is uncommon in patients with cancer; if you get left upper belly (abdonimal) pain, pain below the left rib cage or pain at the tip of your shoulder since this may relate to a problem with your spleen (splenomegaly).
ARDS je manje čest u bolesnika koji boluju od raka; ako osjetite bol u gornjem lijevom dijelu trbuha, bol ispod lijevog rebrenog luka ili bol u vrhu ramena, budući da to može biti povezano s tegobama sa slezenom (splenomegalija).
are 65 years of age or older.
te u dobi od 65 godina ili stariji.
are 65 years of age or older; are unable to tolerate the 100 mg dose;
imate 65 godina ili više; ne podnosite dozu od 100 mg;
are a smoker (as this may increase the risk of dental problems).
te pušač (jer to može povećati rizik od problema sa zubima).
Are above 65 years old
Više od 65 godina starosti
Are above 65 years old;
više od 65 godina starosti,
are allergic (hypersensitive) to corifollitropin alfa or any of the other ingredients of this medicine (listed in section 6)
ako ste alergični (preosjetljivi) na korifolitropin alfa ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.);
are allergic (hypersensitive) to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine (listed in section 6)
ako ste alergični na levodopu, karbidopu ili entakapon, ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.),
are allergic (hypersensitive) to rasburicase, other uricases or any of the other ingredients of this medicine (listed in section 6). have a history of haemolytic anaemia (an illness caused by red blood cells being abnormally broken down).
ako ste alergični (preosjetljivi) na razburikazu, druge urikaze ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). ako u povijesti bolesti imate hemolitičku anemiju (bolest uzrokovana prekomjernom razgradnjom crvenih krvnih stanica).
are allergic (hypersensitive) to ribavirin or any of the other ingredients of this medicine (listed in section 6) if you are pregnant or planning to become pregnant (see section “Pregnancy, breast-feeding and fertility”).
te alergični (preosjetljivi) na ribavirin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). ste trudni ili planirate trudnoću (pogledajte dio "Trudnoća, dojenje i plodnost").
are allergic (hypersensitive) to ribavirin or any of the other ingredients this of medicine (listed in section 6). are pregnant or planning to become pregnant (see section “Pregnancy, breast-feeding and fertility”).
te alergični (preosjetljivi) na ribavirin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). ste trudni ili planirate trudnoću (vidjeti dio "Trudnoća,dojenje i plodnost").
are allergic to any interferon.
alergični na bilo koji interferon,
are allergic to any of the ingredients of this medicine (listed in section 6)
ako ste alergični na bilo koji sastojak ovog lijeka (naveden u dijelu 6.)
are allergic to boceprevir or any of the other ingredients of this medicine (listed in section 6)
ako ste alergični na boceprevir ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.)
are allergic to duloxetine or any of the other ingredients of this medicine (listed in section 6)
ako ste alergični na duloksetin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.)
are allergic to duloxetine or any of the other ingredients of this medicine (listed in section 6)
te alergični na duloksetin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.)
are allergic to duloxetine or any of the other ingredients of this medicine (listed in section 6);
ako ste alergični na duloksetin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.)
are allergic to eggs, chicken protein, are allergic to any antibiotic, barium sulphate, formaldehyde, cetyltrimethylammonium bromide (CTAB) and polysorbate 80.
alergični na jaja, pileću bjelančevinu, alergični na bilo koji antibiotik, barijev sulfat, formaldehid, cetiltrimetilamonij bromid (CTAB) i polisorbat 80.
are allergic to eggs, chicken protein, are allergic to any antibiotic, barium sulphate,formaldehyde, cetyltrimethylammonium bromide (CTAB) and polysorbate 80.
alergični na jaja, pileću bjelančevinu, alergični na bilo koji antibiotik, barijev sulfat, formaldehid, cetiltrimetilamonij bromid (CTAB) i polisorbat 80.
are allergic to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine (listed in section 6)
ako ste alergični na levodopu, karbidopu ili entakapon, ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.),
are allergic to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine (listed in section 6)
ako ste alergični na levodopu, karbidopu ili entakapon, ili neki drugi sastojak ovog lijeka (naveden u dijelu 6..),
are allergic to lurasidone or any of the other ingredients of this medicine (listed in section 6)
ako ste alergični na lurasidon ili neki drugi sastojak ovog lijeka (naveden u dijelu 6)
are allergic to other medicines belonging to the group “oxazolidinones” (e.g., linezolid, cycloserine). are taking certain medicines known as tricyclics or SSRIs (selective serotonin reuptake inhibitors) to treat depression, for example,
ako ste alergični na druge lijekove koji pripadaju skupini "oksazolidinona" (na primjer linezolid, cikloserin); ako uzimate određene lijekove poznate kao triciklički antidepresivi ili selektivni inhibitori ponovne pohrane serotonina (SSRI) za liječenje depresije, primjerice
are allergic to peginterferon alfa-2b or any of the other ingredients of this medicine (listed in section 6).
alergični na peginterferon alfa-2b ili neki drugi sastojak ovog lijeka (naveden u dijelu 6),
Are allergic to pitolisant or any of the other ingredients of this medicine (listed in section 6).
ako ste alergični na pitolizant ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
are allergic to ribavirin or any of the other ingredients of this medicine (listed in section 6). are pregnant or planning to become pregnant (see section “Pregnancy and breast-feeding”).
ako ste alergični na ribavirin ili bilo koji drugi sastojak ovog lijeka (naveden u dijelu 6) ako ste trudni ili planirate trudnoću (pogledajte dio “Trudnoća i dojenje”)
are allergic to ribavirin or any of the other ingredients of this medicine (listed in section 6). are pregnant or planning to become pregnant. (see section “Pregnancy and breast-feeding”)
ako ste alergični na ribavirin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6). ako ste trudni ili planirate trudnoću (vidjeti dio "Trudnoća i dojenje").
are allergic to tadalafil or any of the other ingredients (see section 6). are taking any form of nitrates such as amyl nitrite, used in the treatment of chest pain.
ako ste alergični na tadalafil ili neki drugi sastojak (vidjeti dio 6.) ako uzimate bilo koji oblik nitrata, npr. amil nitrit, koji se koristi za ublažavanje boli u prsima.
are allergic to tadalafil or any of the other ingredients of this medicine (listed in section 6).
ako ste alergični na tadalafil ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
are allergic to tegafur, gimeracil, oteracil or any of the other ingredients of this medicine (listed in section 6).
ako ste alergični na tegafur, gimeracil, oteracil ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
are allergic to vedolizumab or any of the other ingredients of this medicine (listed in section 6). have an active severe infection, for example, tuberculosis, blood poisoning, severe gastroenteritis, nervous system infection
te alergični na vedolizumab ili neki drugi sastojak ovog lijeka (naveden u dijelu 6) imate aktivnu tešku infekciju, na primjer tuberkulozu, trovanje krvi, teški gastroenteritis, infekciju živčanog sustava
are an adult who has or had a severe nervous or mental disorder, confusion, unconsciousness, or have had thoughts of suicide or have attempted suicide or have a history of substance abuse (e.g., alcohol or drugs).. have ever had depression or develop symptoms associated with depression (e.g. feeling of sadness, dejection, etc.) while on treatment with Ribavirin this medicine (see section 4.
odrasla osoba koja ima ili je imala teške živčane ili psihičke poremećaje, smetenost, nesvjesticu, ili ste razmišljali o samoubojstvu ili pokušali samoubojstvo, ili ste u prošlosti zlorabili opojne droge (npr. alkohol ili droge). ikada imali depresiju ili razvili simptome povezane s depresijom (npr. osjećaj tuge, potištenost i sl.) dok ste se liječili s lijekom ovim lijekom (vidjeti dio 4.
are an adult who has or had a severe nervous or mental disorder, confusion, unconsciousness, or have had thoughts of suicide or have attempted suicide or have a history of substance abuse (e.g., alcohol or drugs).. have ever had depression or develop symptoms associated with depression (e.g. feeling of sadness, dejection, etc.) while on treatment with this medicine (see section 4.
odrasla osoba koja ima ili je imala teške živčane ili psihičke poremećaje, smetenost, nesvjesticu, ili ste razmišljali o samoubojstvu ili pokušali samoubojstvo, ili ste u prošlosti zlorabili opojne droge (npr. alkohol ili droge). ikada imali depresiju ili razvili simptome povezane s depresijom (npr. osjećaj tuge, potištenost i sl.) dok ste se liječili s ovim lijekom (vidjeti dio 4.
are at risk of low sodium levels (for example if you are taking diuretics, especially if you are elderly)
imate rizik od pojave niske razine natrija (primjerice, ako uzimate diuretike, osobito ako ste starija osoba)
are at risk of low sodium levels (for example if you are taking diuretics, especially if you are elderly)
imate rizik od pojave niskih razina natrija (na primjer, ako uzimate diuretike, osobito ako ste starija osoba)
are at risk of low sodium levels (for example if you are taking diuretics, especially if you are elderly);
imate rizik od pojave niske razine natrija (primjerice, ako uzimate diuretike, osobito ako ste starija osoba)
are bedridden;
te nepokretni i vezani uz krevet,
are breast feeding (see section 4.6) already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils < 1.5 x 109/l and/or a platelet count of  100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6) bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, na što ukazuje početni broj neutrofila < 1,5 x 109/l i/ili broj trombocita < 100 x 109/l
are breast feeding (see section 4.6) already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils < 1.5 x 109/l and/or a platelet count of  100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6) bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, na što ukazuje početni broj neutrofila < 1,5 x 109/l i/ili broj trombocita < 100 x 109/l.
are breast feeding (see section 4.6) already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils <1.5 x 109/l and/or a platelet count of < 100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6) bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, na što ukazuje početni broj neutrofila < 1,5 x 109/1 i/ili broj trombocita < 100 x 109/1.
are breast-feeding
ako dojite
are breast-feeding
dojite
are breast-feeding (see section 4.6) already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils < 1.5 x 109/l and/or a platelet count of < 100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6) bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, na što ukazuje početni broj neutrofila < 1,5 x 109/l i/ili broj trombocita < 100 x 109/l.
are breast-feeding (see section 4.6) already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils < 1.5 x 109/l and/or a platelet count of < 100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6) bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, što se odnosi na početni broj neutrofila < 1,5 x 109/l i/ili broj trombocita < 100 x 109/l.
are breast-feeding (see section 4.6). already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils < 1.5 x 109/l and/or a platelet count < 100 x 109/l.
bolesnica koje doje (vidjeti dio 4.6). bolesnika s teškom depresijom koštane srži prije započinjanja prvog ciklusa, što se odnosi na početni broj neutrofila < 1,5 x 109/1 i/ili broj trombocita < 100 x 109/1.
are breast-feeding.
ako dojite
are currently being treated with another medicine which may cause liver damage are taking other medicines containing duloxetine (see ‘Other medicines and ARICLAIM’)
e trenutačno liječite nekim drugim lijekom koji može uzrokovati oštećenje jetre uzimate druge lijekove koji sadrže duloksetin (vidjeti ‘Drugi lijekovi i ARICLAIM’)
are currently being treated with another medicine which may cause liver damage are taking other medicines containing duloxetine (see ‘Other medicines and Cymbalta’)
ako se trenutačno liječite nekim drugim lijekom koji može izazvati oštećenje jetre ako uzimate druge lijekove koji sadrže duloksetin (pogledajte ‘Drugi lijekovi i Cymbalta’)
are currently being treated with another medicine which may cause liver damage are taking other medicines containing duloxetine (see ‘Other medicines and Duloxetine Lilly’)
ako se trenutačno liječite nekim drugim lijekom koji može izazvati oštećenje jetre ako uzimate druge lijekove koji sadrže duloksetin (pogledajte ‘Drugi lijekovi i Duloksetin Lilly’)
are currently being treated with another medicine which may cause liver damage are taking other medicines containing duloxetine (see ‘Other medicines and Duloxetine Mylan’)
ako se trenutačno liječite nekim drugim lijekom koji može izazvati oštećenje jetre ako uzimate druge lijekove koji sadrže duloksetin (pogledajte ‘Drugi lijekovi i Duloxetine Mylan’)
are currently being treated with another medicine which may cause liver damage are taking other medicines containing duloxetine (see ‘Other medicines and Xeristar’)
ako se trenutačno liječite nekim drugim lijekom koji može izazvati oštećenje jetre ako uzimate druge lijekove koji sadrže duloksetin (pogledajte ‘Drugi lijekovi i Xeristar’)